GEP20186857B - Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria - Google Patents

Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria

Info

Publication number
GEP20186857B
GEP20186857B GEAP201313844A GEAP2013013844A GEP20186857B GE P20186857 B GEP20186857 B GE P20186857B GE AP201313844 A GEAP201313844 A GE AP201313844A GE AP2013013844 A GEAP2013013844 A GE AP2013013844A GE P20186857 B GEP20186857 B GE P20186857B
Authority
GE
Georgia
Prior art keywords
potentiating
activity
saturated nitrogen
antibiotic against
against mycobacteria
Prior art date
Application number
GEAP201313844A
Other languages
English (en)
Inventor
De Droit Et De La Sante De Lille 2 Universite
Original Assignee
De Droit Et De La Sante De Lille 2 Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Droit Et De La Sante De Lille 2 Universite filed Critical De Droit Et De La Sante De Lille 2 Universite
Publication of GEP20186857B publication Critical patent/GEP20186857B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
GEAP201313844A 2012-12-21 2013-12-20 Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria GEP20186857B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1203548A FR3000065A1 (fr) 2012-12-21 2012-12-21 Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes

Publications (1)

Publication Number Publication Date
GEP20186857B true GEP20186857B (en) 2018-06-11

Family

ID=48521019

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201313844A GEP20186857B (en) 2012-12-21 2013-12-20 Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria

Country Status (23)

Country Link
US (1) US9957249B2 (enExample)
EP (1) EP2935212B1 (enExample)
JP (1) JP6515035B2 (enExample)
KR (1) KR20150138152A (enExample)
CN (1) CN104955804B (enExample)
AU (1) AU2013366503B2 (enExample)
BR (1) BR112015014279A2 (enExample)
CA (1) CA2895606A1 (enExample)
CL (1) CL2015001640A1 (enExample)
CR (1) CR20150319A (enExample)
EA (1) EA028076B1 (enExample)
FR (1) FR3000065A1 (enExample)
GE (1) GEP20186857B (enExample)
IL (1) IL239504B (enExample)
MA (1) MA38275B1 (enExample)
MX (1) MX2015008029A (enExample)
PE (1) PE20151327A1 (enExample)
PH (1) PH12015501427B1 (enExample)
SG (1) SG11201504492UA (enExample)
TN (1) TN2015000202A1 (enExample)
UA (1) UA117922C2 (enExample)
WO (1) WO2014096378A1 (enExample)
ZA (1) ZA201503719B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
ES2865402T3 (es) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
EP3668853B1 (en) * 2017-08-16 2021-09-29 GlaxoSmithKline Intellectual Property Development Limited Novel compounds
JP2020531577A (ja) 2017-08-16 2020-11-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規化合物
EP3668879B1 (en) * 2017-08-16 2021-09-29 GlaxoSmithKline Intellectual Property Development Limited Novel compounds
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
EP1118612A1 (en) * 2000-01-21 2001-07-25 Universita Degli Studi di Firenze Piperazine derivatives possesing nootropic activity
TW593556B (en) 2002-12-27 2004-06-21 Ind Tech Res Inst Dichroic dye, composition thereof, and liquid crystal composition and liquid-crystal display element containing the same
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
TW200938203A (en) * 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
WO2009080432A2 (en) 2007-12-21 2009-07-02 Eth Zurich Composition for treatment of tuberculosis
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
CN102256966B (zh) * 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
CN102458393B (zh) 2009-06-25 2014-08-20 生物验证系统股份公司 治疗肺结核的组合物
KR101179508B1 (ko) * 2010-06-24 2012-09-07 한국과학기술연구원 1,6-이치환-3-아미노-4,5,6,7-테트라하이드로-1Ｈ-피라졸로［3,4-ｃ］피리딘-7-온 화합물 및 이 화합물의 제조방법
US8962658B2 (en) 2011-10-25 2015-02-24 Universite De Droit Et De La Sante De Lille 2 Fluoralkylcarbonyl-oxadiazoles
CA2873075A1 (en) * 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
AU2013292046C1 (en) * 2012-07-20 2018-03-15 Bayer Pharma Aktiengesellschaft Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes

Also Published As

Publication number Publication date
SG11201504492UA (en) 2015-07-30
PH12015501427A1 (en) 2015-09-14
US9957249B2 (en) 2018-05-01
AU2013366503A1 (en) 2015-07-09
TN2015000202A1 (en) 2016-10-03
FR3000065A1 (fr) 2014-06-27
EA028076B1 (ru) 2017-10-31
MA38275A1 (fr) 2017-11-30
IL239504B (en) 2018-10-31
CR20150319A (es) 2015-09-14
CL2015001640A1 (es) 2016-01-29
UA117922C2 (uk) 2018-10-25
PH12015501427B1 (en) 2015-09-14
WO2014096378A1 (fr) 2014-06-26
MA38275B1 (fr) 2018-09-28
IL239504A0 (en) 2015-08-31
ZA201503719B (en) 2016-11-30
CA2895606A1 (fr) 2014-06-26
JP2016503778A (ja) 2016-02-08
AU2013366503B2 (en) 2018-02-01
HK1215254A1 (zh) 2016-08-19
JP6515035B2 (ja) 2019-05-15
EA201590828A1 (ru) 2015-11-30
EP2935212A1 (fr) 2015-10-28
MX2015008029A (es) 2015-10-30
KR20150138152A (ko) 2015-12-09
US20150307471A1 (en) 2015-10-29
PE20151327A1 (es) 2015-10-12
BR112015014279A2 (pt) 2017-07-11
CN104955804B (zh) 2018-02-09
EP2935212B1 (fr) 2019-02-27
CN104955804A (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
GEP20186857B (en) Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
PH12017500755A1 (en) 2 substituted cephem compounds
PH12016501813A1 (en) 1,3-benzodioxole derivative
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
NZ602311A (en) Anti-infective compounds
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
GEP20186838B (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
BR112012024796A2 (pt) inibidores de integrase macrocíclicos
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX360858B (es) Compuesto heterocíclico que contiene nitrógeno parcialmente saturado.
MY196172A (en) Tricyclic Spiro Compound
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
EP3932917A3 (en) Substituted phenyloxazolidinones for antimicrobial therapy
NZ740051A (en) Tetracycline compounds